Ukraine purchases over 14,000 Remdesivir vials for treatment of COVID-19 patients

"On August 31, the State Enterprise Medical Procurement of Ukraine signed an agreement for the purchase of 14,346 vials of the Remdesivir drug. It is used to treat patients with coronavirus infection. Four qualified participants took part in the auction. Thanks to the highly competitive procedure, it was possible to achieve savings of UAH 1.5 million, which is 23.8% of the expected cost of the drug. Thus, instead of UAH 6.3 million, UAH 4.8 million will be spent on the purchase. The cost of one vial is UAH 333.87," the ministry’s press service reports.

The Ministry of Health noted that the purchase took place according to a simplified procedure, since Remdesivir is included in the list of goods necessary to prevent the spread of COVID-19.

The ministry reminded that State Enterprise Medical Procurement of Ukraine is purchasing Remdesivir for the second time. The first purchase took place in September-October 2020.

According to the current purchase agreement, the contracted supplier must provide an indicative schedule for the delivery of goods within 14 working days from the date of signing such an agreement.

Remdesivir, sold under the brand name Veklury, has been developed by Gilead Sciences, Inc. Remdesivir is approved by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adult and pediatric patients.

ish